Signal transduction pathway of cell proliferation induced by EGF and TGF-α in endometrial cancer

Zhi-hong AI,Lian-hua YIN,You-ji FENG
DOI: https://doi.org/10.16073/j.cnki.cjcpt.2008.05.019
2008-01-01
Abstract:OBJECTIVE: To explore the signal transduction pathway of cell proliferation induced by epidermal growth factor (EGF) and transformation growth factor-α (TGF-α) in endometrial cancer. METHODS: Ishikawa endometrial cancer cells were treated by EGF and TGF-α with different concentrations. Cell proliferation was tested by MTT assay. The phosphorylation of ERK1/2, key member of MAPK pathway, and the expression of Survivin protein, key molecular of regulating proliferation were analyzed by Western blot at different time points after the treatment by EGF and TGF-α. Ishikawa cells were then pretreated by U0126, the specific inhibitor of MAPK pathway, and the effects on cell proliferation and Survivin expression by EGF and TGF-α were also observed. RESULTS: EGF and TGF-α on different concentrations all stimulated Ishikawa cell proliferation. Compared to the control, cell proliferation rates treated by 0.1, 1, 10, 100 ng/mL EGF were (112.12±10.23)%, (138.39±6.85)%, (165.50±15.20)% and (162.86±15.17)%, respectively; cell proliferation rates treated by 0.1, 1, 10, 100 ng/mL TGF-α were (102.87±6.44)%, (121.97±3.51)%, (144.42±11.60)% and (141.12±13.50)%, respectively. EGF and TGF-α also induced prompt phosphorylation of ERK1/2 and increased Survivin levels to 8.35 and 9.42 times. U0126 completely inhibited the phosphorylation of ERK1/2 induced by EGF and TGF-α. Blocking MAPK pathway by U0126 also neutralized the enhancement of cell proliferation and the upregulation of Survivin protein expressions induced by EGF and TGF-α. CONCLUSION: EGF and TGF-α can stimulate the growth of endometrial cancer cells via upregulating the expression of Survivin protein through activating MAPK pathway.
What problem does this paper attempt to address?